Argatroban Antithrombin Anticoagulant
E-mail to a ColleagueArgatroban Site Map
Search Argatroban
Argatroban Home

About Argatroban
Argatroban Clinical Efficacy
Argatroban Safety Profile
Mechanism of Action for Argatroban
Argatroban Dosage & Administration
Argatroban Dosing Calculator
Argatroban Conversion to Oral Anticoagulant Therapy
How is Argatroban Supplied
Argatroban FAQs
Argatroban Emergency Availability
About Heparin-Induced Thrombocytopenia (HIT)

Argatroban & HIT Case Studies

Abstracts, News & Events About Argatroban

Argatroban Materials, Tools & Resources

CME Web Sites

Important Safety Information About Argatroban

Dosing & Indications About Argatroban

Argatroban Dosing Calculator

Pharmacy Case Presentation

Initiating oral anticoagulant therapy

Once the decision is made to initiate oral anticoagulant therapy, it is important to recognize the potential for combined effects on the INR with coadministration of Argatroban and warfarin (see Effect on International Normalized Ratio).[2,9,10]

A loading dose of warfarin should not be used.
Initiate therapy using the expected daily dose of warfarin.
To avoid prothrombotic effects and to ensure continuous anticoagulation when initiating warfarin, it is recommended to overlap therapy with Argatroban and warfarin.
There are insufficient data available to recommend the duration of the overlap.

Figure 1. Conversion to Oral Anticoagulant Therapy[2]
Conversion to Oral Anticoagulant Therapy
*For infusion of Argatroban of 2 mcg/kg/min, the INR on monotherapy may be estimated from the INR on cotherapy (see full Prescribing Information).
If the dose of Argatroban is >2 mcg/kg/min, temporarily reduce to a dose of 2 mcg/kg/min 4-6 hours prior to measuring the INR.[11]

Effect on INR

Coadministration of Argatroban and warfarin produces a combined effect on the laboratory measurement of INR values[2]
The combination of Argatroban and warfarin does not cause further reduction in vitamin K-dependent factor Xa activity than that which is seen with warfarin alone
The previously established relationship between INR and bleeding risk is altered during combination therapy.[2] For example, an INR of 4 on cotherapy does not have the same bleeding risk as an INR of 4 on warfarin monotherapy
In a retrospective analysis of patients receiving Argatroban who were converted to warfarin, increased INR were not associated with an increase in major bleeding[12]

Coadministration of warfarin and Argatroban at doses up to 2 mcg/kg/min

The INR value for warfarin alone (INRW) can be calculated from the INR value for the combination regimen of Argatroban and warfarin as described in Effect on International Normalized Ratio.[2] The INR should be measured daily while Argatroban and warfarin are coadministered. In general, with doses of Argatroban up to 2 mcg/kg/min, Argatroban can be discontinued when the INR is >4 on combined therapy.[2]

After Argatroban is discontinued, repeat the INR measurement in 4 to 6 hours.[2] If the repeat INR is below the desired therapeutic range, resume the infusion of Argatroban and repeat the procedure daily until the desired therapeutic range on warfarin alone is reached.[2] The relationship between INR obtained on combined therapy and INR obtained on warfarin alone is dependent on both the dose of Argatroban and the thromboplastin reagent used (see Effect on International Normalized Ratio in the FAQs).[2]

Coadministration of warfarin and Argatroban at doses greater than 2 mcg/kg/min

For doses greater than 2 mcg/kg/min, the relationship between INR on warfarin alone and warfarin plus Argatroban is less predictable (see Effect on International Normalized Ratio).[2] To predict the INR on warfarin alone, temporarily reduce the dose of Argatroban to a dose of 2 mcg/kg/min. Repeat the INR on Argatroban and warfarin 4 to 6 hours after reduction of Argatroban, and follow the process outlined above for dosing Argatroban at up to 2 mcg/kg/min.[2]